275 related articles for article (PubMed ID: 16790293)
41. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
[TBL] [Abstract][Full Text] [Related]
42. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
[TBL] [Abstract][Full Text] [Related]
44. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
Ichiki M; Kawasaki M; Takayama K; Ninomiya K; Kuba M; Iwami F; Miyazaki N; Oishi K; Takeo S; Aizawa H; Nakanishi Y
Cancer Chemother Pharmacol; 2006 Sep; 58(3):368-73. PubMed ID: 16395589
[TBL] [Abstract][Full Text] [Related]
45. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Caponigro F; Gentile M; Marzano N; Gravina A; Dimitri P; Costagliola G; Ferraro A; Ferrante G; De Marino V; Illiano A
J Clin Oncol; 1999 Mar; 17(3):921-6. PubMed ID: 10071285
[TBL] [Abstract][Full Text] [Related]
46. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
[TBL] [Abstract][Full Text] [Related]
47. Results of paclitaxel (day 1 and 8) and carboplatin given on every three weeks in advanced (stage III-IV) non-small cell lung cancer.
Yumuk PF; Turhal NS; Gumus M; Hatabay NF; Turken O; Ozkan A; Salepci T; Aliustaoglu M; Ahiskali R
BMC Cancer; 2005 Jan; 5():10. PubMed ID: 15667664
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
49. Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Pectasides D; Aspropotamitis A; Halikia A; Visvikis A; Antoniou F; Kalantaridou A; Karvounis N; Batzios S; Athanassiou A
J Clin Oncol; 1999 Dec; 17(12):3816-21. PubMed ID: 10577854
[TBL] [Abstract][Full Text] [Related]
50. A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Hasegawa Y; Miura D; Kitamura C; Suzuki T; Kobayashi K; Sato N
Chemotherapy; 2013; 59(5):346-53. PubMed ID: 24821009
[TBL] [Abstract][Full Text] [Related]
51. A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Pino MS; Gamucci T; Mansueto G; Trapasso T; Narducci F; Giampaolo MA; Fariello AM; Sperduti I; Ceribelli A; Cognetti F
Lung Cancer; 2008 Jun; 60(3):381-6. PubMed ID: 18068853
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Abratt RP; Lee JS; Han JY; Tsai CM; Boyer M; Mok T; Kim SW; Lee JS; Brnabic AJ; Reece WH; Lehnert M
J Thorac Oncol; 2006 Feb; 1(2):135-40. PubMed ID: 17409842
[TBL] [Abstract][Full Text] [Related]
53. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
[TBL] [Abstract][Full Text] [Related]
54. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
[TBL] [Abstract][Full Text] [Related]
56. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Kelly K; Mikhaeel-Kamel N; Pan Z; Murphy J; Prindiville S; Bunn PA
Clin Cancer Res; 2000 Sep; 6(9):3474-9. PubMed ID: 10999731
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
58. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
59. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
Rosati G; Rossi A; Nicolella G; Panza N
Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Burris HA; Hainsworth JD; Erland JB; Morrissey LH; Kalman LA; Hon JK; Scullin DC; Smith SW; Greco FA
Semin Oncol; 2000 Feb; 27(1 Suppl 2):9-13. PubMed ID: 10697030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]